GlassScriptPhysician profile
Gemmalin Endriga
NPI 1821250929
$837.97
in general payments reported to CMS, 2019-2025
16 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $49.09 · 2023: $282 · 2024: $362 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $152.91 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $151.80 | 2023-2024 | |
| Genentech USA, INC. | $105.54 | 2023-2025 | Venclexta |
| Janssen Biotech, INC. | $98.09 | 2024-2025 | Erleada, Balversa, Akeega |
| Emd Serono, INC. | $48.64 | 2024 | |
| Coloplast Corp | $39.99 | 2023-2024 | Speedicath |
| Sun Pharmaceutical Industries INC. | $39.23 | 2024 | |
| Dendreon Pharmaceuticals LLC | $33.24 | 2024 | Provenge |
| Amgen INC. | $26.22 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Incyte Corporation | $25.94 | 2023 | Pemazyre, Monjuvi |
| Celgene Corporation | $23.76 | 2023 | Reblozyl |
| Genzyme Corporation | $21.81 | 2022 | |
| Exelixis INC. | $21.15 | 2023 | Cabometyx |
| Abbvie INC. | $18.36 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.25 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $15.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gemmalin Endriga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.